Krista Lanctôt, PhD, Sunnybrook Research Institute, University of Toronto, Canada, discusses a study investigating nabilone for the treatment of agitation in Alzheimer’s disease (AD). The study found a significant decrease in agitation, as measured by the Neuropsychiatric Inventory (NPI), in the nabilone phase compared to the placebo phase, although there was no significant Clinical Global Impression of Change (CGI-C). Dr Lanctot then goes on to speak about a post hoc analysis that investigated predictors of response to nabilone, mentioning that a larger trial is planned to validate these predictors. This interview took place at the 17th Clinical Trials on Alzheimer’s Disease (CTAD) congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
